Valeant Pharmaceuticals International
Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): May 6, 2004


Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
         
Delaware   1-11397   33-0628076
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (IRS Employer
Identification No.)

3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip Code)

(714) 545-0100
(Registrant’s telephone number, including area code)



 


TABLE OF CONTENTS

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
Item 12. Results of Operations and Financial Condition.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1


Table of Contents

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

     (c) Exhibits

     
Exhibit Number
  Description
99.1
  Press release dated May 6, 2004.

Item 12. Results of Operations and Financial Condition.

     On May 6, 2004, the Company issued a press release announcing a preliminary estimate of results of operations in the first fiscal quarter of 2004 and financial condition at March 31, 2004. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

     The information in this report, including the exhibit attached hereto, will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report

-1-


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
Date: May 6, 2004   VALEANT PHARMACEUTICALS INTERNATIONAL
 
       
  By:   /s/Bary G. Bailey
      Bary G. Bailey
      Executive Vice President and
      Chief Financial Officer

-2-


Table of Contents

EXHIBIT INDEX

     
Exhibit Number
  Description
99.1
  Press release dated May 6, 2004.

-3-